Related Experiment Video
Updated: May 24, 2025

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
The potential impact of RNA splicing abnormalities on immune regulation in endometrial cancer
Minyue Cao1, Jiayu Yan1, Yan Ding1
1Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Abstract:
RNA splicing controls the post-transcriptional level of gene expression, allowing for the synthesis of many transcripts with various configurations and roles. Variations in RNA splicing regulatory factors, including splicing factors, signaling pathways, epigenetic modifications, and environmental factors, are typically the origin of tumor-associated splicing anomalies. Furthermore, thorough literature assessments on the intricate connection between tumor-related splicing dysregulation and tumor immunity are currently lacking. Therefore, we also thoroughly discuss putative targets associated with RNA splicing in endometrial cancer (EC) and the possible impacts of aberrant RNA splicing on the immune control of tumor cells and tumor microenvironment (TME), which contributes to enhancing the utilization of immunotherapy in the management of EC and offers an alternative viewpoint for the exploration of cancer therapies and plausible prognostic indicators.
Insights
RNA splicing anomalies are linked to cancer. This study explores RNA splicing
Area of Science:
- Molecular Biology
- Cancer Research
- Immunology
Background:
- RNA splicing regulates gene expression, producing diverse transcripts.
- Aberrant RNA splicing in tumors arises from altered regulatory factors.
- The link between splicing dysregulation and tumor immunity is not well-understood.
Purpose of the Study:
- To review RNA splicing anomalies in endometrial cancer (EC).
- To discuss the impact of aberrant splicing on tumor immunity and the tumor microenvironment (TME).
- To identify potential RNA splicing targets for EC immunotherapy.
Main Methods:
- Literature review and analysis.
- Discussion of RNA splicing regulatory factors.
- Exploration of the relationship between splicing, tumor immunity, and EC.
Main Results:
- Tumor-associated splicing anomalies are common and linked to regulatory factor variations.
- Aberrant RNA splicing affects immune control within the tumor microenvironment.
- Potential RNA splicing targets in EC were identified.
Conclusions:
- Understanding RNA splicing's role in EC can improve immunotherapy strategies.
- Aberrant splicing impacts tumor immune evasion and progression.
- RNA splicing offers novel therapeutic targets and prognostic markers for EC.
Related Concept Videos
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
MicroRNAs
RNA Stability
Experimental RNAi

